+91-8668442535

Neurotrophic Keratitis Market By Treatment (Preservative Free Artificial Tears, Topical Antibiotics, Tarsorraphy, Amniotic Membrane Transplantation, Bandage Contact Lenses, Recombinant Human Nerve Growth Factor) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Neurotrophic keratitis is an orphan disease that is primarily caused by the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings present in the corneal region of the eye.

Traditional therapies are employed to suppress the clinical manifestations occurring at different stages of the disease. Currently, RGN-259, developed by ReGenTree, LLC, is in phase III clinical trial study for the treatment of neurotrophic keratitis.

Market Synopsis

Recent EMA approval of Oxervate and priority review designation approved by the USFDA will popularise the recombinant human nerve growth factor during the forecast period.

Neurotrophic keratitis is a rare degenerative disease that results in a loss of corneal sensation and dampens the healing process. The global prevalence rate of neurotrophic keratitis is reported to be 5 per 10,000 individuals. The treatment options adopted for neurotrophic keratitis depend on the severity and stage of the disease. Artificial tears are prescribed for all stages due to their ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. Topical antibiotics are mostly prescribed during stage 2 of the disease for prophylactic treatment of infection.

Despite pharmacological treatment, in stage 3 of the disease, surgical interventions such as cartography and amniotic membrane transplantation are employed to heal corneal ulceration. The recent approval of Oxervate by the EMA and priority review designation approved by the USFDA will popularise the utilization of recombinant human nerve growth factor for the treatment of neurotrophic keratitis during the forecast period.

Rising prevalence of neurotrophic keratitis and an affordable reimbursement scenario drive market growth in North America.

North America is presently responsible for 33% of the market share and is leading the regional segment for neurotrophic keratitis. According to the American Academy of Ophthalmology (AAO), approximately 65,000 people in the United States are suffering from this rare disease.

The chief contributing factors to its dominance in the regional market are the rising prevalence of neurotrophic keratitis and the affordability of the reimbursement scenario pertaining to the medication used for its treatment.

Europe trails North America in the regional market with a share of 28.5%, primarily due to strategic collaboration between government healthcare agencies and academic research institutes for the development of novel drugs for treating neurotrophic keratitis in Europe.

The European Medicines Agency (EMA) has designated neurotrophic keratitis as an orphan disease and has granted it fast-track status for drug development and sale in the region. Asia Pacific holds a 16% market share owing to the increasing incidence rate of neurotrophic keratitis in the geriatric population and supportive regulatory scenarios provided by regional healthcare agencies.

Periods of History and Forecast

This research report presents the analysis of each segment from 2017 to 2027,considering2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by treatment and by geography.

Pharmaceutical companies specializing in providing medication for the treatment of neurotrophic keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG, CooperVision, Dompe Farmaceutici S.p.A., Johnson & Johnson, Novartis AG, ReGenTree, LLC., and Walgreens.

Key questions are answered in this report.

  • Which strategic collaborations, mergers, and acquisitions are taking place in the neurotrophic keratitis market?
  • Which key players are manufacturing medicines for the treatment of neurotrophic keratitis?
  • What is the disease etiology of neurotrophic keratitis, and what medicines are prescribed as per the different stages of the disease?
  • What is Oxervate, and how will it perform during the forecast period?
  • What will be the market performance of developing regions such as Asia Pacific and Latin America in the neurotrophic keratitis market?

Frequently Asked Question:

The market for Neurotrophic Keratitis Market is expected to reach USD$ XX in 2027.

The Neurotrophic Keratitis Market is expected to see significant CAGR growth over the coming years, at 5.2%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59723
Report Format:   PDF
Pages:   120
Rating:    4.2 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support